Dyadic International, Inc. announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus?. Dyadic?s proprietary Dapibus? filamentous fungal based microbial protein production platform will be used to design, develop, and commercialize innovative animal-free dairy enzymes and related proteins and biomaterials.

Under the agreement, Dyadic will receive an upfront payment of $0.6 million for product development and licensing its Dapibus? platform, in addition to potential success fees, milestones, and royalties.